Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Sales and Divestitures: 2016-2019

  • Akebia Therapeutics' Gains from Sales and Divestitures fell 60.52% to $323,136 in Q4 2019 from the same period last year, while for Dec 2019 it was $323,136, marking a year-over-year decrease of 60.52%. This contributed to the annual value of $323,136 for FY2019, which is 60.52% down from last year.
  • Per Akebia Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $323,136 for Q4 2019, which was down 60.52% from $818,395 recorded in Q4 2018.
  • In the past 5 years, Akebia Therapeutics' Gains from Sales and Divestitures registered a high of $818,395 during Q4 2018, and its lowest value of $90,566 during Q4 2017.
  • Over the past 3 years, Akebia Therapeutics' median Gains from Sales and Divestitures value was $323,136 (recorded in 2019), while the average stood at $410,699.
  • In the last 5 years, Akebia Therapeutics' Gains from Sales and Divestitures soared by 803.64% in 2018 and then crashed by 60.52% in 2019.
  • Quarterly analysis of 4 years shows Akebia Therapeutics' Gains from Sales and Divestitures stood at $108,688 in 2016, then fell by 16.67% to $90,566 in 2017, then soared by 803.64% to $818,395 in 2018, then crashed by 60.52% to $323,136 in 2019.
  • Its Gains from Sales and Divestitures stands at $323,136 for Q4 2019, versus $818,395 for Q4 2018 and $90,566 for Q4 2017.